Celldex Therapeutics Inc. (NASDAQ:CLDX): Zacks View on 1Q14 Earnings and Pipeline Update


Dallas, Texas 05/12/2014 (FINANCIALSTRENDS) –Celldex Therapeutics, Inc. (NASDAQ:CLDX) recently announced its 1Q14 earnings on May 1, 2014 where it posted more than expected losses of $0.33 per share, wider than 1Q13 losses of $0.23 per share. The 1Q14 losses also missed Zacks Consensus Estimate of $0.26 per share. However, 1Q14 revenues were reported at $0.4 million, 82.8% down from 1Q13 and better than Zack Consensus Estimate of nil. The decline in revenue was largely because of lower royalties on Rotarix from GlaxoSmithKline plc (ADR) (NYSE:GSK) because of its termination of agreement with Glaxo.

1Q14 Details:

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s 1Q14 research and development expenses increased 92.1% to $27.1 million when compared with 1Q13. This was largely attributed to development of glembatumumab vedotin and rindopepimut as well as expansion of varlilumab related study.

The company also reported 46% year over year increase in its 1Q14 general and administrative expenses because of higher cost of professional services, personnel related expenses as well as commercial planning costs for glembatumumab vedotin and rindopepimut.

2 H 14 Outlooks:

Celldex Therapeutics, Inc. (NASDAQ:CLDX) also provided an update on its pipeline products along with 1Q14 earnings release. The company noted that it expects continues patient enrolment for its Phase-III study on rindopepimut which is expected to be completed by mid-2014. The study is testing the potential use of drug for positive glioblastoma multiform (GBM). Moreover the company is also enrolling patients for its rindopepimut related Phase-II study for recurrent GBM and it expects the study to be completed by end of 2014.

Moreover, the company also expects to begin Phase-II studies for squamous cell lung cancer and metastatic melanoma including glembatumumab vedotin.

On Friday, Celldex Therapeutics’ stock gained 15.33% and closed at $12.79. However, the stock plunged 11.85% in overall, during the last week. At its previous close, the stock is about 67% below its 52 week high of $38.84 and just about 16% above its 52 week low of $11.02.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.